Towards a novel 3D cell culture model to test the therapeutic efficacy of Affimers in the treatment of HER2 overexpressing breast cancer
Towards a novel 3D cell culture model to test the therapeutic efficacy of Affimers in the treatment of HER2 overexpressing breast cancer
批准号:
2310402
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2016
资助国家:
英国
项目状态:
已结题
起止时间:
2016 至 --
中文摘要
乳腺癌(BC)是女性中最常见的癌症。人表皮受体2 (HER2)在15- 30%的BC中过表达,与管腔亚型相比,其预后较差。单克隆抗体(MAb)曲妥珠单抗目前用于其治疗。小鼠模型已经并将继续是有价值的BC模型,然而,为了解决3r问题,在研究中减少、改进和替代它们的使用是可取的。在这里,我们正在研究一种新的HER2+ BC体外3D培养模型。将HER2过表达细胞系BT-474在无基质的epiFL培养基中培养成球形。球体显示肿瘤的特征,如坏死的核心和三维结构,因此比二维培养模型更能转化为临床。然后在SeedEZ支架中培养细胞。支架是亲水的,由玻璃纤维组成,允许球体在它们之间形成。SeedEZ与PerfusionPal一起培养,以更接近地模拟体内肿瘤的环境。此外,已经鉴定出结合HER2的抗体替代蛋白支架Affimers,并将研究其抑制HER2+细胞生长的作用。这是为了创建一个完全人性化的3D模型,以测试和比较Affimers与曲妥珠单抗治疗HER2+ BC的疗效,潜在地减少临床前药物测试对动物的需求。
英文摘要
Breast cancer (BC) is the most commonly diagnosed cancer amongst women. Human epidermal receptor 2 (HER2) is overexpressed in 15-30 % of BC and is associated with poorer prognosis with comparison to the luminal subtypes. The monoclonal antibody (MAb) Trastuzumab is currently used for its treatment.Mouse models have and continue to be valuable models of BC, however, to address the 3 R's it is desirable to reduce, refine and replace their use in research. Here, a novel in vitro 3D culture model of HER2+ BC is being investigated. The HER2 overexpressing cell line BT-474 were cultured as spheroids in a matrix-free medium, epiFL. Spheroids show characteristics of a tumour such as a necrotic core and 3D structure so are more translational to the clinic than 2D culture models. Cells were then cultured in SeedEZ scaffolds. The scaffolds are hydrophilic consisting of glass fibers that allow spheroids to form in between them. SeedEZ were cultured with PerfusionPal to more closely mimic the environment of a tumour in vivo. Furthermore Affimers, an antibody replacement protein scaffold, that bind HER2 have been identified and their effects on inhibiting HER2+ cell growth will be studied. This is towards the creation of a fully humanised 3D model to test and compare the efficacy of Affimers in comparison to Trastuzumab in the treatment of HER2+ BC, potentially reducing the need for animals in preclinical drug testing.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
Novel-miR-1134调控LHCGR的表达介导拟
穴青蟹卵巢发育的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:崔文晓
-
依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
-
批准号:82304677
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:边兴博
-
依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
-
批准号:82304658
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:刘亚
-
依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
-
批准号:32102747
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:李婉雁
-
依托单位:
novel_circ_001042/miR-298-5p/Capn1轴调节线粒体能量代谢在先天性肛门直肠畸形发生中的作用机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:唐晓冰
-
依托单位:
novel-miR-59靶向HMGAs介导儿童早衰症细胞衰老的作用及机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:58万元
-
批准年份:2021
-
负责人:张瑜
-
依托单位:
novel_circ_008138/rno-miR-374-3p/SFRP4调控Wnt信号通路参与先天性肛门直肠畸形发生的分子机制研究
-
批准号:82070530
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:白玉作
-
依托单位:
miRNA-novel-272通过靶向半乳糖凝集素3调控牙鲆肠道上皮细胞炎症反应的机制研究
-
批准号:32002421
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:修云吉
-
依托单位:
m6A修饰介导的lncRNA WEE2-AS1转录后novel-pri-miRNA剪切机制在胶质瘤恶性进展中的作用研究
-
批准号:82072775
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:薛皓
-
依托单位:
miRNA/novel_167靶向抑制Dmrt1的表达在红鳍东方鲀性别分化过程中的功能研究
-
批准号:31902347
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2019
-
负责人:闫红伟
-
依托单位: